Melinta Therapeutics, Inc. (MLNT) Expected to Earn Q3 2018 Earnings of ($1.15) Per Share
Melinta Therapeutics, Inc. (NASDAQ:MLNT) – Investment analysts at Jefferies Financial Group issued their Q3 2018 EPS estimates for shares of Melinta Therapeutics in a report released on Tuesday, September 11th. Jefferies Financial Group analyst D. Hoang forecasts that the biotechnology company will post earnings per share of ($1.15) for the quarter. Jefferies Financial Group has a “Buy” rating and a $15.00 price objective on the stock. Jefferies Financial Group also issued estimates for Melinta Therapeutics’ Q4 2018 earnings at ($1.09) EPS, FY2018 earnings at ($4.67) EPS, FY2019 earnings at ($2.89) EPS, FY2020 earnings at ($0.88) EPS, FY2021 earnings at $0.01 EPS and FY2022 earnings at $1.24 EPS.
Other analysts also recently issued research reports about the company. Zacks Investment Research downgraded Melinta Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. Cantor Fitzgerald began coverage on Melinta Therapeutics in a research report on Sunday, July 1st. They set a “buy” rating and a $15.00 price target for the company. WBB Securities upgraded Melinta Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price target for the company in a research report on Friday, May 25th. HC Wainwright began coverage on Melinta Therapeutics in a research report on Tuesday. They set a “buy” rating and a $14.00 price target for the company. Finally, ValuEngine upgraded Melinta Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $10.13.
Melinta Therapeutics (NASDAQ:MLNT) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.14) by ($0.24). The business had revenue of $12.02 million for the quarter, compared to the consensus estimate of $12.06 million. Melinta Therapeutics had a negative net margin of 348.51% and a negative return on equity of 67.60%.
A number of large investors have recently added to or reduced their stakes in MLNT. Schwab Charles Investment Management Inc. lifted its position in Melinta Therapeutics by 56.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 74,668 shares of the biotechnology company’s stock worth $553,000 after buying an additional 27,047 shares during the last quarter. Engineers Gate Manager LP bought a new stake in Melinta Therapeutics in the 1st quarter worth approximately $157,000. Northern Trust Corp lifted its position in Melinta Therapeutics by 48.0% in the 1st quarter. Northern Trust Corp now owns 166,112 shares of the biotechnology company’s stock worth $1,229,000 after buying an additional 53,889 shares during the last quarter. BlackRock Inc. lifted its position in Melinta Therapeutics by 41.8% in the 1st quarter. BlackRock Inc. now owns 857,398 shares of the biotechnology company’s stock worth $6,344,000 after buying an additional 252,943 shares during the last quarter. Finally, Sphera Funds Management LTD. lifted its position in Melinta Therapeutics by 21.9% in the 1st quarter. Sphera Funds Management LTD. now owns 243,896 shares of the biotechnology company’s stock worth $1,805,000 after buying an additional 43,896 shares during the last quarter. Institutional investors own 68.60% of the company’s stock.
Melinta Therapeutics Company Profile
Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP.
Recommended Story: How to Invest in an Index Fund
Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.